

Article

Beta-Amyloid Oligomers Activate Apoptotic BAK Pore for Cytochrome *c* Release

Jaewook Kim,¹ Yoosoo Yang,¹ Seung Soo Song,² Jung-Hyun Na,^{1,2} Kyoung Joon Oh,³ Cherlhyun Jeong,¹ Yeon Gyu Yu,² and Yeon-Kyun Shin^{1,4,*}

¹Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea; ²Department of Chemistry, Kookmin University, Seoul, Republic of Korea; ³Department of Biochemistry and Molecular Biology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois; and ⁴Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, Iowa

ABSTRACT In Alzheimer's disease, cytochrome *c*-dependent apoptosis is a crucial pathway in neuronal cell death. Although beta-amyloid (A β) oligomers are known to be the neurotoxins responsible for neuronal cell death, the underlying mechanisms remain largely elusive. Here, we report that the oligomeric form of synthetic A β of 42 amino acids elicits death of HT-22 cells. But, when expression of a bcl-2 family protein BAK is suppressed by siRNA, A β oligomer-induced cell death was reduced. Furthermore, significant reduction of cytochrome *c* release was observed with mitochondria isolated from BAK siRNA-treated HT-22 cells. Our *in vitro* experiments demonstrate that A β oligomers bind to BAK on the membrane and induce apoptotic BAK pores and cytochrome *c* release. Thus, the results suggest that A β oligomers function as apoptotic ligands and hijack the intrinsic apoptotic pathway to cause unintended neuronal cell death.

INTRODUCTION

Alzheimer's disease (AD), a progressive neurodegenerative disorder, may be identified by the accumulation of senile plaques, neurofibrillary tangles, and substantial loss of brain mass (1,2). Mounting evidence clearly indicates that intracellular beta-amyloid (A β) oligomers are the neurotoxins responsible for neuronal cell death in AD (3–7). Neuronal cell death, commonly found among AD patients and pathologically significant due to its irreversibility, may be a result of apoptosis, specifically the release of cytochrome *c* from the mitochondria (8,9). Cytochrome *c* release, which is a pivotal step in apoptosis, triggers a cascade of caspase activation that leads to cell death. Under normal apoptotic conditions, cytochrome *c* is thought to be released through apoptotic pores in the mitochondrial outer membrane (MOM), which are induced by the activation of BAK or BAX via caspase-8-cleaved BID (tBID, p15 BID) (10–12).

The notion that A β oligomers induce neuronal cell death via apoptosis in AD is based on apoptotic markers found in postmortem AD brain such as DNA fragmentations, increased bcl-2 family protein expression, increased caspase activities (13,14), and cell-level studies that show elevated levels of cytochrome *c* found in the cytosol (12,15). Moreover, some studies demonstrate that A β oligomers elicit cytochrome *c* release from isolated mitochondria (16,17). It has been reported that amyloid precursor protein and

A β localize to the mitochondria and lead to mitochondrial dysfunction by interacting with mitochondrial proteins, by blocking mitochondrial import channels, by disrupting electron-transport chain, or by increasing reactive-oxygen species products (18,19). However, these mitochondrial dysfunctions do not satisfactorily explain the A β -induced cytochrome *c* release.

In this work, we investigate the direct involvement of a bcl-2 family protein BAK in A β -induced cytochrome *c* release and neuronal cell death. In cells, suppression of BAK expression with siRNA resulted in reduced cell death by A β oligomers. Isolated mitochondria from siRNA-treated cells showed decreased release of cytochrome *c* by A β oligomers, together linking BAK to A β oligomer-induced cytochrome *c* release and cell death. Further on, in a well-defined *in vitro* setting, we unambiguously show that A β oligomers interact with BAK and trigger the release of cytochrome *c* from MOM-like vesicles. The results raise the possibility that A β oligomers hijack the cytochrome *c*-dependent apoptotic pathway by interacting with BAK even in the absence of the death signal, leading to cell death.

MATERIALS AND METHODS

Preparation of A β oligomers

The synthetic peptide wild-type A β (1–42) was purchased from American Peptide (Sunnyvale, CA). As described in Dahlgren et al. (20) and Ahmed et al. (21), the A β (1–42) peptide was initially dissolved to 1 mM in hexafluoroisopropanol (Sigma-Aldrich, St. Louis, MO) and separated into aliquots in sterile microcentrifuge tubes. Hexafluoroisopropanol was removed under vacuum in a SpeedVac (Thermo Fisher Scientific, Rockford,

Submitted May 29, 2014, and accepted for publication July 25, 2014.

*Correspondence: colishin@iastate.edu

Jaewook Kim and Yoosoo Yang contributed equally to this work.

Editor: Edward Stuenkel.

© 2014 by the Biophysical Society
0006-3495/14/10/1601/8 \$2.00



<http://dx.doi.org/10.1016/j.bpj.2014.07.074>

IL) and the peptide film was stored desiccated at -80°C . To make oligomers, cold phosphate-buffered saline was added to bring the peptide to a final concentration of $10\ \mu\text{M}$ and incubated at 4°C for 18 h (see Fig. S1 in the Supporting Material).

Expression and purification of recombinant proteins

The mouse BAK protein containing amino acids 16–184 (BAK ΔC) was prepared with a C-terminal histidine ($6\times$) tag using pPosKJ-sBAK-cHis plasmid as described in Oh et al. (22). N-terminal His6-tagged Bid (p22 BID) was purified, and p7/p15 BID or cBID, an activated form of BID, was prepared from the p22BID protein after cleavage with caspase-8, as described in Oh et al. (23). The fragment p22BID forms a tight complex as p7/p15 BID (cBID). All protein preparations were stored in 18% glycerol, 20 mM Tris buffer (pH 7.4), and 150 mM KCl at -80°C . The protein concentration was determined using the bicinchoninic acid protein assay kit (Thermo Fisher Scientific), and purified proteins were examined with 15% sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the purity was at least 95% for all proteins (see Fig. S3 B).

Cell culture and gene silencing

HT-22 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin/streptomycin at 37°C in a 5% CO_2 incubator. After 24 h incubation, BAK siRNA transfection was performed with an siRNA transfection reagent (Santa Cruz Biotechnology, Dallas, TX) according to the manufacturer's instructions. Briefly, transfection reagent and BAK siRNA or nonfunctional control siRNA were dissolved separately in a dilution buffer and the respective transfection mixtures were added to the antibiotic and serum-free cell culture medium to a final concentration of 20 nM siRNA. Six hours after transfections, the $2\times$ medium (DMEM with 20% FBS and 2% antibiotics) was added to the siRNA-treated HT22 cells, and the cells were further incubated for 18 h.

Mitochondria isolation and cytochrome *c* release assay

Mitochondria were isolated using a Mitochondrial Isolation Kit for Cultured Cells (Thermo Fisher Scientific) according to the manufacturer's instructions. Isolated mitochondria were incubated with the indicated concentrations of cBID and A β oligomers for 45 min at room temperature in mitochondria buffer (150 mM KCl, 5 mM MgCl_2 , 1 mM EGTA, 25 mM HEPES, 1 mM DTT pH 7.5) under constant stirring using a Thermomixer ($V_{\text{final}} = 100\ \mu\text{L}$; Eppendorf, Hamburg, Germany). Reaction mixtures were centrifuged at $14,000\times g$ for 15 min, with cytochrome *c* quantitated using a colorimetric ELISA (Invitrogen) according to the manufacturer's protocol. Briefly, supernatant fraction was added to the well of a microtiter plate pre-coated with monoclonal anti-cytochrome *c* antibody, followed by adding $100\ \mu\text{L}$ of cytochrome *c* biotin conjugate solution for 1 h at room temperature (RT). Then, $100\ \mu\text{L}$ of streptavidin-HRP working solution was added for 30 min at RT. After adding $100\ \mu\text{L}$ of stabilized chromogen, equal volume of stop solution was also added and the product was measured on a spectrophotometer at 450 nm.

Immunoblotting

For Western blot analysis, HT-22 cells were lysed with RIPA buffer (Cell Signaling Technology, Danvers, MA) with Protease Inhibitor Cocktail (Calbiochem, Darmstadt, Germany). After centrifugation at $15,000\times g$ for 15 min at 4°C , total protein amounts were determined with the BCA

Protein Assay kit (Bio-Rad, Hercules, CA). Equal amounts of protein lysates were separated by SDS-PAGE electrophoresis, and transferred to nitrocellulose membrane. The blot was probed with an anti-BAK rabbit polyclonal antibody (G-23) at 4°C overnight. Membranes were then exposed to the HRP-conjugated rabbit anti-goat secondary antibody (Sigma-Aldrich) followed by a chemiluminescence detection of antibody binding (Thermo Fisher Scientific). Equal protein loading was controlled by reprobing the membrane with a monoclonal anti- β -actin antibody (Sigma-Aldrich).

Cofloatation assay

To measure the binding properties of A β oligomers to proteoliposomes (liposomes reconstituted with BAK ΔC only or BAK ΔC /cBID or cBID only), each vesicle ($100\ \mu\text{M}$) was incubated with A β oligomers for 30 min at room temperature, then air-fused at high speed (Airfuse; Beckman Instruments, Brea, CA). The amounts of bound A β oligomers were measured by Dot blot using anti-amyloid oligomer antibody (A11; Millipore, Billerica, MA). The proteins bound on the liposomes were detected by Western blot using the BAK (G-23) or BID (FL-195) antibodies purchased from Santa Cruz Biotechnology.

Cytochrome *c* labeling and MOM-like vesicle preparation

For dye labeling, cytochrome *c* (from equine heart, Sigma-Aldrich) in phosphate-buffered saline (137 mM NaCl, 10.13 mM Na_2HPO_4 , 2.68 mM KCl, 1.76 mM KH_2PO_4 , pH 7.4) was incubated with twofold excess of Cy3 succinimide ester (Lumiprobe, Hallandale Beach, FL) for 6 h at 4°C , such that $\sim 1\text{--}2$ Cy3 dyes were labeled per cytochrome *c*. Free dyes were removed from the solution by using the PD-10 desalting column (GE Healthcare, Piscataway, NJ).

Lipids were purchased from Avanti Polar Lipids (Alabaster, AL). Lipids in organic solvent were mixed, in accordance with previous work (22,24), with the molar ratio 36:21.9:9:8:20:5 for POPC (1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine)/POPE (1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoethanolamine)/POPS (1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoserine)/cholesterol/cardiopin (from beef heart)/DOGS-NTA-Ni (nickel salt; 1,2-dioleoyl-*sn*-glycero-3-([N-5-amino-1-carboxypentyl]-iminodiacetic acid) succinyl).

For the surface-attachment, 0.1 mol % of biotin-DPPE (1,2-dipalmitoyl-*sn*-glycero-3-phosphoethanolamine-N-(cap biotinyl)) lipid was added to the lipid solution. The lipid mixture was completely dried using the nitrogen gas and further dried with a vacuum pump for at least 3 h. The dried lipid film was resuspended in $\sim 15\ \mu\text{M}$ Cy3-labeled cytochrome *c*. After five freeze/thaw cycles, large unilamellar vesicles (~ 200 nm diameter) were prepared by extrusion through polycarbonate filters (Avanti Polar Lipids) (see Fig. S3 C). Untrapped cytochrome *c* was removed by air-fused centrifugation (Airfuse; Beckman Instruments).

Single-vesicle cytochrome *c* release assay

The flow chambers were assembled on a quartz imaging surface functionalized with PEG (polyethylene glycol) and PEG-biotin molecules (molar ratio 40:1; Laysan Bio, Arab, AL) followed by streptavidin (0.2 mg/mL, Sigma-Aldrich) incubation for 10 min. After washing several times, the MOM-like vesicles are injected into the chamber and immobilized, followed by the washing of free vesicles with $500\ \mu\text{L}$ injection of buffer (50 mM Tris-HCl, pH 7.4, 150 mM KCl). Once immobilized, photobleaching safe laser intensity is secured, then BAK ΔC , cBID, and other proteins are injected into the flow chamber. The vesicles were monitored with a prism-type total internal reflection fluorescence (TIRF) microscope attached to an electron-multiplying charge-coupled device camera for digital image processing (see Fig. S4 A).

Photobleaching test

Photobleaching is induced by the destruction of fluorophores via light exposure that results in a decrease in fluorescence emission. A laser intensity that does not alter the fluorescence intensity of the MOM-like vesicle for a 10- or 20-min observation period must be secured. We used the first flow chamber (out of a total of 10) in every slide to calibrate the maximum laser intensity that does not induce photobleaching (see Fig. S4 B). All experiments within the respective slide were carried out below the photobleaching safe intensity.

TIRF data processing

The image streaming of the sample chamber from the electron-multiplying charge-coupled device camera connected to the TIRF microscope was collected using single molecule software developed by Dr. Jong-Bong Lee at POSTECH (Pohang University of Science and Technology, Pohang, South Korea). The time traces of the fluorescence intensity of the MOM-like vesicles were then extracted using interactive data language. Once the time traces for the vesicles were obtained, preliminary categorizations of the fluorescence intensity, specifically detection of stepwise drops that correspond to cytochrome *c* release, were performed using a step-detection program (25). The categorized data were then manually examined one by one to exclude any false-positives.

Purification of α -synuclein and preparation of large α -synuclein oligomers

Recombinant GST-fused α -synuclein was expressed in *Escherichia coli* Rosetta (DE3) pLysS (Novagen, Darmstadt, Germany). The cells were grown at 37°C in LB medium with 100 μ g/mL ampicillin until the absorbance at 600 nm reached 0.6–0.8. Isopropyl β -D-1-thiogalactopyranoside (0.5 mM final concentration) was then added to induce protein expression. Cells were grown for another 12 h at 16°C. GST fusion protein was purified with affinity chromatography using glutathione-agarose beads and then cleaved off from the resin by incubating with thrombin at room temperature for 2 h. To prepare large α -synuclein oligomers, 10 μ M of α -synuclein was mixed with 100 μ M dopamine in 20 mM sodium phosphate buffer (pH 7) at 37°C for 72 h. After incubation, the mixture was centrifuged to remove large aggregates at 13,000 \times g for 5 min at 4°C. Then, the supernatant was concentrated using Ultracel 10 K membrane (Millipore). Large oligomers were purified by size exclusion chromatography using Superdex 200 10/300 GL (GE Healthcare) and concentrated again using Ultracel 10 K-membrane (26).

Dynamic light scattering (DLS)

The size distribution of MOM-like vesicles and A β oligomers were analyzed by DLS with Zetasizer nano Zs (Malvern Instruments, Malvern, Worcestershire, UK) at a fixed angle of 173° at 25°C. The MOM-like vesicles (10 μ M lipid concentration) were subjected to the DLS measurement after 10-min centrifugation at 13,000 rpm. The data was analyzed by the cumulative method using software provided by the instrument.

RESULTS

BAK is involved in cytochrome *c* release by A β oligomers

We prepared synthetic 42-amino-acid-long A β peptide and converted it to oligomers by incubation at 4°C for 16 h (21). The DLS analysis of A β oligomers shows a single peak at \sim 17 nm (see Fig. S1 A), which is in coherence

with previous studies that report 10–20-nm-sized A β oligomers are pentamers/hexamers (21,27). We tested the toxicity of our synthetic A β oligomers on HT-22 cells with the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. We delivered A β oligomers directly into the cytoplasm of HT-22 cells using the protein transfection method and measured cell viability (Fig. 1 A). Although A β oligomers did not harm cell viability at concentrations up to 1000 nM (see Fig. S2) in the period of first 3 h, exogenous A β oligomers induce cell death at longer exposure times (Fig. 1 A) (28).

To address the potential role of BAK in A β oligomers-induced cell death, we took a gene-silencing approach using BAK siRNA that reduced BAK mRNA and consequently, protein levels (Fig. 1 B). We observed that A β




FIGURE 1 A β oligomer-induced cell death and cytochrome *c* release from siRNA-transfected and normal HT-22 cells. (A) Cell viability of HT-22 cells was evaluated with the MTT assay, 12 h and 24 h, after treatment of the indicated concentrations of A β oligomers. Transfected A β oligomers were confirmed with Dot blot using anti- β amyloid (6E10) antibody. The data represent the mean \pm SD of three independent experiments. (B) Immunoblot analysis of BAK and A β oligomers protein in HT-22 cells using anti-BAK and anti- β amyloid (6E10) antibody. HT-22 cells were pre-treated with/without the 20 nM BAK siRNA for 18 h. A quantity of 1000 nM A β oligomers were treated with protein transfection reagents. Anti- β -actin and anti-Bid antibodies used as control is shown. (C) A β oligomer-induced cell death was compared in normal and BAK KD HT-22 cells using the MTT assay. The data represent the mean \pm SD of three independent experiments (** P < 0.01; *** P < 0.005 compared with A β oligomers-treated (1 μ M) normal HT-22 cells pretreated with vehicle). (D) Measurement of cytochrome *c* release from isolated mitochondria of HT-22 cells using a colorimetric ELISA assay kit (Invitrogen). The data represent the mean \pm SD of four independent experiments. Concentrations are given in moles of monomeric A β . To see this figure in color, go online.

oligomer-induced cell death in BAK knockdown (KD) HT-22 cells was significantly reduced when compared to untreated HT-22 cells (Fig. 1 C), strongly suggesting that A β oligomers may play a role in the BAK-dependent apoptotic pathway.

To narrow down the potential targets of A β oligomers, we extracted the mitochondria from both normal and BAK KD HT-22 cells and compared the amount of cytochrome *c* release induced by A β oligomers with the ELISA assay (28,29). Remarkably, for mitochondria from BAK KD HT-22 cells, a significant reduction in cytochrome *c* release was observed when compared with that from normal cells (Fig. 1 D). Thus, our results show that A β oligomers most likely target BAK for cytochrome *c* release.

As controls, we induced the cytochrome *c* release from isolated mitochondria with cBID (p7/p15 BID), which is a potent apoptotic trigger for both BAK and BAX. As expected,

we observed a cBID-concentration-dependent increase in cytochrome *c* release, suggesting that cytochrome *c* release machinery works normally in isolated mitochondria. Furthermore, significantly less cytochrome *c* release out of mitochondria extracted from BAK KD HT-22 cells than that from a normal cell at 500 nM cBID is consistent with reduced BAK protein levels in the siRNA-treated cells.

Single-vesicle cytochrome *c* release assay

To investigate the effects of A β oligomers on apoptotic BAK pores without involving other mitochondrial protein factors, we developed a well-defined in vitro single-vesicle assay that can monitor the real-time dynamics of cytochrome *c* release from single MOM-like vesicles (Fig. 2 A). MOM-like vesicles were encapsulated with Cy3-labeled cytochrome *c* and immobilized on the quartz




FIGURE 2 In vitro single-vesicle cytochrome *c* release assay. (A) Experimental design of the single-vesicle cytochrome *c* release assay system. The initial state starts with Cy3-labeled cytochrome *c* encapsulated MOM-like vesicles tethered to a PEG-coated quartz surface via biotin-streptavidin interactions (red arrow). Then BAK Δ C and cBID are injected into the flow chamber, inducing apoptotic BAK pores followed by cytochrome *c* release. (Inset, below) Soluble form of recombinant mouse BAK protein (BAK Δ C, residues 16–184) with a C-terminal hexa-histidine tag (see Fig. S3 A in the Supporting Material) tethered onto an NTA lipid. (B) Representative time traces of Cy3-labeled cytochrome *c* release via apoptotic BAK pore formation. (C) The cumulative histogram of cytochrome *c* release when treated with the indicated concentrations of recombinant apoptotic proteins observed for 10 min (100-ms time binning). (D) Total cytochrome *c* release histogram of the indicated concentrations of recombinant apoptotic proteins after 10 min. Data in panels C and D represents the mean \pm SD of five independent experiments. To see this figure in color, go online.

imaging surface, which was monitored with a TIRF microscope. Next, a mixture of recombinant BAK without the transmembrane helix (BAK Δ C) and cBID is injected into the flow chamber. BAK Δ C is a recombinant form of BAK that has been frequently used for the structural and functional investigations of BAK (22,24,30,31). Hexa-histidine tag on the C-terminal end of BAK Δ C tethers onto the Ni-NTA lipid, mimicking its membrane anchor (Fig. 2 A, inset below; and see Fig. S3 A). When BAK Δ C is activated by cBID, we observed the release of Cy3-labeled cytochrome *c*, which resulted in a sudden drop in the fluorescence intensity (Fig. 2 B). Intensity drop due to release differs from slow intensity decline due to photobleaching (see Fig. S4 B).

As expected, we observed an increase in cytochrome *c* release events as BAK Δ C and cBID concentrations were increased. Specifically, after a 10-min observation period, ~11% of the surface-immobilized vesicles exhibited cytochrome *c* release at 40 nM for both BAK Δ C and cBID (Fig. 2, C and D). Cytochrome *c* release was not observed in the absence of either BAK Δ C or cBID (see Table S1 in the Supporting Material), consistent with the results from previous in vitro experiments (22,30). The necessity of both BAK Δ C and cBID was also confirmed by using sulforhodamine (SRB)-dextran fluorescent dyes in our in vitro single-vesicle assay (see Table S2). Thus, the results validate our assay for the study of apoptotic BAK pores and cytochrome *c* release (30,32–34).

A β oligomers induce formation of apoptotic BAK pores

Here, we take an in vitro approach to investigate whether A β oligomers and BAK alone can induce cytochrome *c* release. Because some studies relate A β oligomers with direct MOM permeabilization (15,35,36), we tested whether A β oligomers could independently induce cytochrome *c* release from protein-free MOM-like vesicles. High concentration (1 μ M, in monomer concentration) injections of A β oligomers, into the flow, in the absence of BAK Δ C did not exhibit any fluorescence intensity change (see Table S3), assuring that at concentrations lower than 1 μ M, A β oligomers alone could not induce protein pores or membrane permeability that would enable cytochrome *c* release.

When A β oligomers and BAK Δ C were injected into the flow chamber, cytochrome *c* release is clearly observed from the vesicles (Fig. 3 A and see Table S4). Specifically, ~12% of the vesicles displayed cytochrome *c* release, after 10 min, when treated with 200 nM A β oligomers (in monomer concentration) and 40 nM BAK Δ C.

Our in vitro single-vesicle results suggest that A β oligomers directly induce apoptotic BAK pores and thus, it is highly likely that there is a physical interaction between A β oligomers and BAK. To test this hypothesis, we performed a modified cofloatation assay in a cell-free membrane environment. A β oligomers were incubated with

BAK Δ C, cBID, or BAK Δ C/cBID proteoliposomes, respectively. Vesicles were collected from the pellets after centrifugation, then separated by SDS-PAGE and transferred onto Western blot.

The results show that A β oligomers bind strongly with BAK Δ C and BAK Δ C/cBID proteoliposomes. However, a weak interaction is also observed between A β oligomers and cBID proteoliposomes. The weak intensity of A β oligomers binding to cBID appears to represent nonspecific A β oligomers binding to the lipid bilayer as opposed to direct binding with cBID, because a comparable intensity was also observed in the mixture of A β oligomers and protein-free liposome. Consistently, the supernatant fractions contain a high concentration of unbound A β oligomers when incubated with cBID, whereas significantly fewer free A β oligomers were present when incubated with BAK Δ C (Fig. 3 B). Therefore, our results confirm that A β oligomers indeed directly bind with BAK Δ C tethered on the MOM-like vesicle.

A β oligomers accelerate BAK/cBID mediated apoptotic pores

We have identified that cBID and A β oligomers induce apoptotic BAK pores mutually independently. Now, we investigated whether the two can work synergistically. Experiments were performed with various concentrations of A β oligomers whereas BAK Δ C and cBID concentrations were fixed at 40 nM. Although it is not obvious at low concentrations of A β oligomers, the results clearly show that cBID and A β oligomers are synergic in enhancing cytochrome *c* release at 200 nM (Fig. 3 C). There is a twofold increase compared to the linear sum of those when cBID and A β oligomers are individually present (Fig. 3 D). The results raise the possibility that A β oligomers have the capacity to accelerate cBID-induced apoptotic BAK pore formation, in addition to its ability to induce BAK pore formation on their own.

Do α -synuclein, tau induce apoptotic BAK pores?

Next, we investigated the specificity of A β oligomers by testing the effects of other well-known dementia-inducing proteins (DIPs) on apoptotic BAK pore formation (1,5,37). We first tested whether the various forms, either monomer or oligomers, of tau, α -synuclein, or A β (1 μ M) could independently release cytochrome *c* from the vesicles without BAK Δ C. After 10 min, cytochrome *c* release did not occur in all cases (see Table S3), providing grounds that the DIPs alone do not puncture the vesicles. Next, we injected BAK Δ C with DIPs. Our results clearly show that only A β oligomers possess the ability to induce apoptotic BAK pores (Fig. 4 A). In addition, we also investigated the pro/anti-apoptotic effects of DIPs on cBID-induced apoptotic BAK pores. Except for A β oligomers, other DIPs did not cause any alterations in the cytochrome *c* release rates (Fig. 4 B). Thus, the results show that A β oligomers




FIGURE 3 Cytochrome *c* release via A β oligomer-induced apoptotic BAK pores. (A) The cumulative histogram of cytochrome *c* release when treated with the indicated concentrations of A β oligomers and 40 nM BAK Δ C observed for 10 min. The data represent the mean \pm SD of five independent experiments. (B) Cofloatation assay of A β oligomers interaction with proteoliposomes. Liposomes treated with BAK Δ C and/or cBID mixed with/without A β oligomers, and precipitated with high-speed centrifugation. The amount of vesicle-bound A β oligomer was quantified by Dot blot. The data represent the mean \pm SD of three independent experiments. The quantification of the bound levels of A β oligomers (red box) was performed with the software QUANTITY ONE (Bio-Rad). (C) The cumulative histogram of cytochrome *c* release when treated with the indicated concentrations of A β oligomers 40 nM BAK Δ C and 40 nM cBID, observed for 10 min. (D) Total cytochrome *c* release histogram of the indicated concentrations of A β oligomers 40 nM BAK Δ C and 40 nM cBID, compared to the sum of 40 nM BAK Δ C, 40 nM cBID, 40 nM BAK Δ C A β oligomers (indicated concentration) after 10 min. Data in panels C and D represent the mean \pm SD of five independent experiments. Concentrations are given in moles of monomeric A β . To see this figure in color, go online.

specifically induce apoptotic pores and accelerate the formation of cBID-induced apoptotic BAK pores.

DISCUSSION

Studies implicate that A β oligomers are the key modulators of cytochrome *c* release in relation to neuronal cell death in AD. A β is known to be produced by enzymatic cleavage of amyloid precursor protein, located on the plasma membrane, and normally excreted to the extracellular space

(1,2,38). However, some studies show that A β is often cleaved prematurely from the ER and Golgi and is also trafficked back into the cytosol in the significant numbers sufficient to cause physiological difficulties (7,39,40). Cell-level studies link A β oligomers with elevation of reactive oxygen species, transition in the MOM permeability, mitochondrial morphological change, and alteration of the expression level of various bcl-2 family proteins (15,18,19,28). It is clear that intracellular A β oligomers target the mitochondria and exhibit neurotoxic effects.




FIGURE 4 The effect of DIPs on apoptotic BAK pores. The cumulative histogram of cytochrome *c* release when treated with the indicated DIPs (200 nM) along with (A) 40 nM BAK Δ C or (B) 40 nM BAK Δ C and 40 nM cBID observed for 10 min. Data represent the mean \pm SD of five independent experiments. Concentrations are given in moles of monomeric A β , tau, and α -synuclein. To see this figure in color, go online.

However, the underlying mechanisms by which A β oligomers induce cytochrome *c* release is yet to be elucidated. Here we show that A β oligomers physically target BAK and hijack the intrinsic apoptotic pathway (Fig. 5).

We observed significantly reduced A β oligomer-induced cell death in BAK KD HT-22 cells. Moreover, A β oligomer-induced cytochrome *c* release out of isolated mitochondria from BAK KD HT-22 cells was reduced when compared with that from mitochondria from normal cells. Thus, these cell-level results establish the connection between A β oligomers and BAK-dependent apoptotic pathway. Our *in vitro* single-vesicle study goes much further by uncovering the underlying mechanisms by which A β oligomers induce cytochrome *c* release and identify that A β oligomers' sole interaction with BAK is sufficient to induce apoptotic BAK pores. Using a cofloatation assay, we show that A β oligomers bind directly with BAK on the membrane, providing the molecular basis for its role in the cytochrome *c*-dependent apoptotic pathway.

Recently, however, Camilleri et al. (17) argued that the disruption of lipid membrane integrity may be the reason for the A β oligomer toxicity on isolated mitochondria. We note that much higher concentrations of A β oligomers were used in their *in vitro* study than in ours, which could have made the vesicles leaky for small contents in their long observation time. In sharp contrast, we did not observe the release of much larger cytochrome *c* in our single-vesicle assay. Furthermore, significantly reduced cytochrome *c* release levels was observed in isolated mitochondria from BAK KD HT-22 cells, which clearly substantiates the role of BAK in A β oligomers-induced cytochrome *c* release.

Interestingly, we also observed vesicle populations with multiple steps in our *in vitro* single-vesicle assay (see

Fig. S5). Had abrupt membrane rupture been the cause of cytochrome *c* release, we would have observed only single-step time traces. Further, experiments employing SRB-dextran displayed content release for a fivefold-higher number of vesicles than when we used Cy3-labeled cytochrome *c*, indicating that some openings in the membrane are large enough to allow SRB-dextran but not sufficient for cytochrome *c*. Thus, our results suggest that A β oligomers indeed induce apoptotic BAK pores.

Our results were possible because of our *in vitro* single-vesicle cytochrome *c* release assay. Previous cell-based assays that measure the amount of cytochrome *c* released from the mitochondria (15,16,28) do not provide temporal information and the closeup examination of the relevant protein machinery is difficult. An ensemble, *in vitro* release assay using small fluorescence probes could provide real-time dynamics and identifications of relevant protein machinery, but are not able to discriminate physiological apoptotic pores (22,30,41). In contrast, the significance of our assay is that we can monitor the cytochrome *c* levels within individual MOM-like vesicles and detect pores sufficient for cytochrome *c* release. Our assay should be generally applicable to the studies of other pro/anti-apoptotic proteins and other protein translocation pores.

Although we show that A β oligomers are sufficient to induce apoptotic BAK pores in a minimalistic setting, we cannot completely exclude the possibility of A β oligomers interacting with other apoptotic bcl-2 family proteins such as BAX (10–12,33,42) or hindering BAK-inhibiting proteins such as VDAC2 (43,44). Also, our BAK KD experiments were conducted using HT-22 cells from the hippocampal neuronal cell line. Because neuronal cell death is common within the cerebral cortex (8,45), further experiments using primary cultured cortical neurons is warranted.

In conclusion, we show that even in the absence of normal apoptotic signals such as tBID, A β oligomers can directly interact with BAK and release cytochrome *c*. Thus, our results suggest that even without a death signal, the presence of A β oligomers alone can trigger neuronal cell death, which is in coherence with the progression of AD. Our results also suggest that A β oligomers have the capacity to amplify the death signal, which could transform a normally tolerable apoptotic signal to a faithful on-signal for cell death.




FIGURE 5 A proposed model of A β oligomer function on apoptotic BAK pore formation. (A) Normal apoptotic pathway; tBID induces conformational change of BAK, inducing membrane insertion followed by oligomerization, which results in apoptotic BAK pores. (B) A β oligomers hijack the apoptotic pathway by inducing BAK conformational change such that apoptotic BAK pores are formed in the absence of the death signal. To see this figure in color, go online.

SUPPORTING MATERIAL

Five figures and four tables are available at [http://www.biophysj.org/biophysj/supplemental/S0006-3495\(14\)00855-8](http://www.biophysj.org/biophysj/supplemental/S0006-3495(14)00855-8).

This work was, in whole or in part, supported by the National Institutes of Health (grant No. R01 GM051290 to Y.-K.S. and grant No. 5 R01 GM097508 to K.J.O.), the Korea Institute of Science and Technology (KIST Institutional Project No. 2E25000), the Electronic Paramagnetic Resonance Center at the Rosalind Franklin University of Medicine and Science (to K.J.O.), and the Startup Fund from the Rosalind Franklin University of Medicine and Science (to K.J.O.).

REFERENCES

- Selkoe, D. J. 2001. Alzheimer's disease: genes, proteins, and therapy. *Physiol. Rev.* 81:741–766.
- Hardy, J. A., and G. A. Higgins. 1992. Alzheimer's disease: the amyloid cascade hypothesis. *Science.* 256:184–185.
- Haass, C., and D. J. Selkoe. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. *Nat. Rev. Mol. Cell Biol.* 8:101–112.
- McLean, C. A., R. A. Cherny, ..., C. L. Masters. 1999. Soluble pool of $A\beta$ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann. Neurol.* 46:860–866.
- Huang, Y., and L. Mucke. 2012. Alzheimer mechanisms and therapeutic strategies. *Cell.* 148:1204–1222.
- Benilova, I., E. Karran, and B. De Strooper. 2012. The toxic $A\beta$ oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat. Neurosci.* 15:349–357.
- LaFerla, F. M., K. N. Green, and S. Oddo. 2007. Intracellular amyloid- β in Alzheimer's disease. *Nat. Rev. Neurosci.* 8:499–509.
- Mattson, M. P. 2000. Apoptosis in neurodegenerative disorders. *Nat. Rev. Mol. Cell Biol.* 1:120–129.
- Castro, R. E., M. M. Santos, ..., C. M. Rodrigues. 2010. Cell death targets and potential modulators in Alzheimer's disease. *Curr. Pharm. Des.* 16:2851–2864.
- Bredesen, D. E., R. V. Rao, and P. Mehlen. 2006. Cell death in the nervous system. *Nature.* 443:796–802.
- Hail, Jr., N., B. Z. Carter, ..., M. Andreeff. 2006. Apoptosis effector mechanisms: a requiem performed in different keys. *Apoptosis.* 11:889–904.
- Jiang, X., and X. Wang. 2004. Cytochrome *c*-mediated apoptosis. *Annu. Rev. Biochem.* 73:87–106.
- Smale, G., N. R. Nichols, ..., W. E. Horton, Jr. 1995. Evidence for apoptotic cell death in Alzheimer's disease. *Exp. Neurol.* 133:225–230.
- Ankarcrona, M., and B. Winblad. 2005. Biomarkers for apoptosis in Alzheimer's disease. *Int. J. Geriatr. Psychiatry.* 20:101–105.
- Sanz-Blasco, S., R. A. Valero, ..., L. Núñez. 2008. Mitochondrial Ca^{2+} overload underlies $A\beta$ oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. *PLoS ONE.* 3:e2718.
- Kim, H. S., J. H. Lee, ..., Y. H. Suh. 2002. Amyloid- β peptide induces cytochrome *c* release from isolated mitochondria. *Neuroreport.* 13:1989–1993.
- Camilleri, A., C. Zarb, ..., N. Vassallo. 2013. Mitochondrial membrane permeabilization by amyloid aggregates and protection by polyphenols. *Biochim. Biophys. Acta.* 1828:2532–2543.
- Spuch, C., S. Ortolano, and C. Navarro. 2012. New insights in the amyloid- β interaction with mitochondria. *J. Aging Res.* 2012:324968.
- Liu, T., S. E. Roh, ..., D. E. Kang. 2013. Cooperative role of RanBP9 and P73 in mitochondria-mediated apoptosis. *Cell Death Dis.* 4:e476.
- Dahlgren, K. N., A. M. Manelli, ..., M. J. LaDu. 2002. Oligomeric and fibrillar species of amyloid- β peptides differentially affect neuronal viability. *J. Biol. Chem.* 277:32046–32053.
- Ahmed, M., J. Davis, ..., S. O. Smith. 2010. Structural conversion of neurotoxic amyloid- β (1–42) oligomers to fibrils. *Nat. Struct. Mol. Biol.* 17:561–567.
- Oh, K. J., P. Singh, ..., D. E. Walters. 2010. Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. *J. Biol. Chem.* 285:28924–28937.
- Oh, K. J., S. Barbuto, ..., S. J. Korsmeyer. 2005. Conformational changes in BID, a pro-apoptotic BCL-2 family member, upon membrane binding. A site-directed spin labeling study. *J. Biol. Chem.* 280:753–767.
- Aluvila, S., T. Mandal, ..., K. J. Oh. 2014. Organization of the mitochondrial apoptotic BAK pore: oligomerization of the BAK homodimers. *J. Biol. Chem.* 289:2537–2551.
- Kalafut, B., and K. Visscher. 2008. An objective, model-independent method for detection of non-uniform steps in noisy signals. *Comput. Phys. Commun.* 179:716–723.
- Choi, B. K., M. G. Choi, ..., Y. K. Shin. 2013. Large α -synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. *Proc. Natl. Acad. Sci. USA.* 110:4087–4092.
- Bitan, G., M. D. Kirkitadze, ..., D. B. Teplow. 2003. Amyloid β -protein ($A\beta$) assembly: $A\beta$ 40 and $A\beta$ 42 oligomerize through distinct pathways. *Proc. Natl. Acad. Sci. USA.* 100:330–335.
- Cha, M. Y., S. H. Han, ..., I. Mook-Jung. 2012. Mitochondria-specific accumulation of amyloid β induces mitochondrial dysfunction leading to apoptotic cell death. *PLoS ONE.* 7:e34929.
- Leshchiner, E. S., C. R. Braun, ..., L. D. Walensky. 2013. Direct activation of full-length proapoptotic BAK. *Proc. Natl. Acad. Sci. USA.* 110:E986–E995.
- Landeta, O., A. Landajuela, ..., G. Basañez. 2011. Reconstitution of proapoptotic BAK function in liposomes reveals a dual role for mitochondrial lipids in the BAK-driven membrane permeabilization process. *J. Biol. Chem.* 286:8213–8230.
- Dai, H., A. Smith, ..., S. H. Kaufmann. 2011. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. *J. Cell Biol.* 194:39–48.
- Karbowski, M., K. L. Norris, ..., R. J. Youle. 2006. Role of Bax and Bak in mitochondrial morphogenesis. *Nature.* 443:658–662.
- Korsmeyer, S. J., M. C. Wei, ..., P. H. Schlesinger. 2000. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome *c*. *Cell Death Differ.* 7:1166–1173.
- Dewson, G., and R. M. Kluck. 2009. Mechanisms by which Bak and Bax permeabilize mitochondria during apoptosis. *J. Cell Sci.* 122:2801–2808.
- Parks, J. K., T. S. Smith, ..., W. D. Parker, Jr. 2001. Neurotoxic $A\beta$ peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. *J. Neurochem.* 76:1050–1056.
- Lin, H., R. Bhatia, and R. Lal. 2001. Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. *FASEB J.* 15:2433–2444.
- Tiraboschi, P., L. A. Hansen, ..., J. Corey-Bloom. 2004. The importance of neuritic plaques and tangles to the development and evolution of AD. *Neurology.* 62:1984–1989.
- Hardy, J. 2009. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. *J. Neurochem.* 110:1129–1134.
- Sakono, M., and T. Zako. 2010. Amyloid oligomers: formation and toxicity of $A\beta$ oligomers. *FEBS J.* 277:1348–1358.
- Li, M., L. Chen, ..., Y. Zhang. 2007. The role of intracellular amyloid- β in Alzheimer's disease. *Prog. Neurobiol.* 83:131–139.
- Schafer, B., J. Quispe, ..., T. Kuwana. 2009. Mitochondrial outer membrane proteins assist Bid in Bax-mediated lipidic pore formation. *Mol. Biol. Cell.* 20:2276–2285.
- Zhang, Y., R. McLaughlin, ..., A. LeBlanc. 2002. Selective cytotoxicity of intracellular amyloid β peptide 1–42 through p53 and Bax in cultured primary human neurons. *J. Cell Biol.* 156:519–529.
- Plötz, M., B. Gillissen, ..., J. Eberle. 2012. Disruption of the VDAC2-Bak interaction by Bcl-x(S) mediates efficient induction of apoptosis in melanoma cells. *Cell Death Differ.* 19:1928–1938.
- Cheng, E. H., T. V. Sheiko, ..., S. J. Korsmeyer. 2003. VDAC2 inhibits BAK activation and mitochondrial apoptosis. *Science.* 301:513–517.
- Niikura, T., H. Tajima, and Y. Kita. 2006. Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. *Curr. Neuropharmacol.* 4:139–147.

SUPPORTING MATERIALS for

“Beta-amyloid oligomers activate apoptotic BAK pore for cytochrome c release”

Jaewook Kim^{1†}, Yoosoo Yang^{1†}, Seung Soo Song², Jung-Hyun Na^{1,2}, Kyoung Joon Oh³, Cherlhyun Jeong¹, Yeon Gyu Yu², and Yeon-Kyun Shin^{1,4*}

¹Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 136-791, Republic of Korea

²Department of Chemistry, Kookmin University, Seoul 136-702, Republic of Korea

³Department of Biochemistry and Molecular Biology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064

⁴Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, IA 50011

SUPPLEMENTARY FIGURES




Figure S1 (A) The intensity versus size distribution obtained from DLS measurements of 5 μ M A β oligomers. The single peak was detected at 16.8 nm. (B) Dot blot analysis using 6E10 (anti-beta amyloid beta antibody) and A11 (anti-amyloid oligomer antibody).




Figure S2 Cell viability test for HT-22 cells against A β oligomers. Dose- and time- dependent effect of A β oligomers on cell viability was measured by using the MTT assay. The data represents the mean \pm s.d. of 3 independent experiments. Concentrations are given in moles of monomeric A β .




Figure S3 (A) Schematic representation of mouse BAK protein constructs. The soluble form of recombinant mouse BAK protein was prepared with a histidine tag, BAKΔC (His 6X) as described in “Materials and Methods”. (B) Recombinant purified proteins and cytochrome c used in this study, separated by SDS-PAGE and visualized by Coomassie Blue staining. (C) Analysis of MOM-like vesicles by DLS. The average mean liposome was 177.8 (\pm 9.6) nm (\pm s.d.).




Figure S4 (A) Schematic diagram of the prism-type TIRF setup. Single green laser (532 nm) creates evanescent field at the interface between quartz imaging surface and flow chamber. (B) Photo-bleaching, no photo-bleaching and cytochrome c release models and their representative emission fluorescence time traces are shown in the respective columns. The first case presents photo-bleaching. When the fluorophores are exposed to high laser intensity the emission intensity decays with time. The second case presents “no photo-bleaching”. In this case the laser intensity is safe in order to monitor the vesicles during the observation period. The third case presents cytochrome c release. The fluorescence intensity decreases but in a stepwise manner, which is distinguishable from photo-bleaching. The laser intensity was set at levels below the “no photo-bleaching” case, therefore the fluorescence intensity leading up to the stepwise drop position is stable.




Figure S5 Representative fluorescence time traces of single vesicles that exhibit multi-step decrease in the presence of apoptotic BAK pores.

SUPPLEMENTARY TABLES

Table S1 Total number of cytochrome c release events from tBID-induced apoptotic BAK pores

BAKΔC (nM)	tBID (nM)	Percentage (mean ± s.d.)	Total observation (number)	
		cytochrome c release	Cytochrome c release	Docked vesicles
0	40	0.00 ± 0.00	0	2890
40	0	0.00 ± 0.00	1	3345
10	10	2.03 ± 0.44	75	3477
20	20	8.70 ± 1.01	257	2837
40	40	11.35 ± 0.91	474	4246

Table S2 Total number of SRB-dextran release events from tBID-induced apoptotic BAK pores

	Percentage (mean ± s.d.)	Total observation (number)	
	SRB-Dextran release	SRB-Dextran release	Docked vesicles
tBID (10 nM)	0.00 ± 0.00	0	2862
BAKΔC (10 nM)	0.00 ± 0.00	0	3762
BAKΔC (10 nM)+tBID (10 nM)	10.25 ± 0.93	321	3202

Table S3 Toxicity test of DIPs on MOM-like vesicles

	Percentage (mean ± s.d.)	Total observation (number)	
	cytochrome c release	Cytochrome c release	Docked vesicles
AβO (1 μM)	0.00 ± 0.00	0	3265
AβM (1 μM)	0.00 ± 0.00	1	2955
αSyn.O (1 μM)	0.00 ± 0.00	1	3012
αSyn.M (1 μM)	0.00 ± 0.00	2	3054
TauA (1 μM)	0.00 ± 0.00	2	2876
TauO (1 μM)	0.00 ± 0.00	0	2971
TauM (1 μM)	0.00 ± 0.00	2	4088

Table S4 Total number of SRB-dextran release events from Aβ oligomer-induced apoptotic BAK pores

	Percentage (mean ± s.d.)	Total observation (number)	
	SRB-Dextran release	SRB-Dextran release	Docked vesicles
AβO (1 μM)	0.00 ± 0.00	0	3265
BAKΔC (10 nM)+AβO (100 nM)	6.55 ± 1.35	270	4372
BAKΔC (10 nM)+tBID (10 nM)+AβO (100 nM)	32.53 ± 4.81	1224	3654